Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible?

• Published in: Rheumatic & musculoskeletal diseases open Vol. 9; no. 2; p. e003158
• Main Authors: Panagiotopoulos, Alexandros, Kapsia, Eleni, Michelakis, Ioannis, Boletis, John, Marinaki, Smaragdi, Sfikakis, Petros P, Tektonidou, Maria G
• Format: Journal Article
• Language: English
• Published: England EULAR 01.06.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: autoimmune diseases; Biopsy; Clinical trials; Collaboration; Connective Tissue Diseases; Creatinine; Female; Glucocorticoids; Humans; Immunosuppressive agents; Kidney; Kidney diseases; Laboratories; Lupus; lupus erythematosus, systemic; Lupus Nephritis; Male; Patients; Proteinuria; Risk Factors; Trends; autoimmune diseases; lupus erythematosus, systemic; lupus nephritis
• ISSN: 2056-5933; 2056-5933
• DOI: 10.1136/rmdopen-2023-003158

ObjectiveA preliminary definition of disease modification (DM) in lupus nephritis (LN) was recently developed focusing on long-term remission and damage prevention, with minimal treatment-associated toxicity. We aimed to further specify aspects of DM criteria in LN, assess DM achievement in a real-world setting and examine potential DM predictors and long-term outcomes.MethodsWe collected clinical/laboratory and histological inception cohort data from biopsy-proven LN patients (82% females) with ≥72 months follow-up at two joint academic centres. Specific criteria for 24-hour proteinuria, estimated glomerular filtration rate (eGFR), renal flares and glucocorticoids dose were set at three time frames (months 0–12, 13–60 and 72) to assess DM. In the first model, DM was achieved if patients fulfilled all four criteria at all three time frames (achievers). In the second model, the continued glucocorticoids reduction criterion was excluded. Logistic regression analyses were performed. Possible different trends in DM achievement between past and recent decades were also investigated.ResultsDM was achieved by 60% of patients, increased to 70% when glucocorticoids excluded from DM criteria. 24-hour proteinuria at 9 months predicted DM achievement (OR 0.72, 95% CI 0.53 to 0.97, p=0.03), but none of baseline characteristics. Among patients with >72 month follow-up, non-achievers had worse renal outcomes (flares, >30% proteinuria increase, eGFR decline) than achievers at the end of follow-up (median 138 months). Patients diagnosed between 1992 and 2005 were found to have significantly lower percentages of DM achievement and met less often the glucocorticoids dose reduction criterion in all three time frames, compared with those diagnosed between 2006 and 2016 (p=0.006 and p<0.01, respectively).ConclusionsDM was achieved by only 60% of LN patients in a real-life setting, partly due to lack of glucocorticoids dose target attainment, while DM failure was associated with worse long-term renal outcomes. This may imply limitations in the effectiveness or implementation of current LN treatments, supporting the need for novel therapeutic strategies.